Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

These jabs work by providing an instruction to the patient’s cells to churn out a particular protein that acts as a flag for ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

Novavax’s COVID-19 vaccine won FDA approval in October 2023. It’s different from the mRNA vaccines developed by Pfizer Inc.

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

BioNTech has agreed to acquire biotechnology company Biotheus for $800 million up front and up to $150 million in milestone payments. The German developer of RNA vaccines and immunotherapies said ...

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...